We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Appeals Court Rules Generic Label Would Direct Docs to Infringe Use Patent
Appeals Court Rules Generic Label Would Direct Docs to Infringe Use Patent
The Federal Circuit upheld two Sanofi patents for its antiarrhythmic drug Multaq (dronedarone) — agreeing with Sanofi’s argument that the drug’s label, which is required to be similar for any generic versions, would ultimately direct physicians to violate the company’s patent on using Multaq to prevent abnormal heart rhythms.